Key Takeaways CRL's RMS segment grew 6.5% in Q3 2025, led by Noveprim, China, CRADL, GEMS and aca/govt. clients.CRL expands via partnerships with Elly's Team, Parker Institute, CHDI Foundation, Deciphex and Akron Bio.CRL faces cautious biotech spending, NIH-dependent revenues, tariffs and competition across segments.Charles River Laboratories International, Inc.’s (CRL) solid prospects in the Research Models and Services (“RMS”) segment are supported by consistent demand for its research model services. The ...

When you and I first met a few years ago, you had an idea and a concept. Now you have a company moving forward with that. I think actually it's a start.Let's explain why having that degree of interaction with what is a robotic arm in that lab environment through natural language is necessary. What is it sold for. Yeah.So we want to give scientists directly, not just engineers with scientists directly, the ability to actually run experiments at scale. And that is why we are building the physical A. I.scienti ...

Medra Raises $52 Million to Speed Drug Discovery With AI Robots https://t.co/TDan8gaAxS ...

For much of the past century drug discovery was dominated by Western firms, the companies collectively often called “big pharma”. No longer https://t.co/ultysqJ1Zt ...

[Music] Welcome to FYI, the 4-year innovation podcast. This show offers an intellectual discussion on technologically enabled disruption because investing in innovation starts with understanding it. To learn more, visit ark-invest.com. [Music] Ark Invest is a registered investment adviser focused on investing in disruptive innovation. This podcast is forformational purposes only and should not be relied upon as a basis for investment decisions. It does not constitute either explicitly or implicitly any prov ...

CHINO HILLS, CALIFORNIA / ACCESS Newswire / November 6, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announced the release of a technical white paper describing ABBIE, a Cas9-guided integrase platform that enables donor-DNA integration without double-strand breaks or viral vectors. Using ABBIE, the team established SKOV3-GYS1, an ovarian cancer cell line with stable ...

Financial Performance - Total revenue reached $17601 million, a 54% increase compared to Q3 2024[12, 17] - Key product revenue grew by 104%, reaching $12 billion[12] - Non-GAAP earnings per share (EPS) increased by $584 to $702[12] - The company raised the midpoint of full-year revenue guidance by over $2 billion[10] Product Highlights - Lilly's U S incretin analogs market share increased to 579% of total prescriptions, with market growth of 36% versus prior year[10, 26] - Mounjaro U S sales were $36 billion, and international sales were $30 billion[56] - Zepbound U S sales were $36 billion, and international sales were $20 million[59] - Verzenio U S sales were $880 million, and international sales were $590 million[62] - Jaypirca Q3 2025 sales were $143 million, with U S TRx increasing 61% vs Q3 2024[24] - Ebglyss Q3 2025 sales were $127 million, with U S TRx growing 41% vs Q2 2025[24] - Omvoh Q3 2025 sales were $65 million[24] - Kisunla Q3 2025 sales were $70 million[24] Strategic Investments - Year-to-date capital investments totaled $53 billion[12] - Research & Development investment was $35 billion, representing 27% of revenue[12] - Marketing, selling & administrative expenses were $27 billion, a 31% increase[12] - $13 billion was distributed via dividends and $07 billion in share repurchases[14] Regulatory and Clinical Updates - Inluriyo (imlunestrant) received U S FDA approval for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer[11] - Kisunla received marketing authorization in Europe for early symptomatic Alzheimer's disease[11] - Orforglipron showed positive results in four additional Phase 3 trials[11] - Jaypirca significantly improved progression-free survival in treatment-naïve CLL/SLL[11]

Drug giant Eli Lilly is teaming up with chip designer Nvidia to build a supercomputer for AI-boosted drug discovery https://t.co/7J2LhEJn5S ...

Core Insights - Eli Lilly and Company is developing the most powerful supercomputer in the pharmaceutical industry in collaboration with NVIDIA, aimed at enhancing drug discovery and development processes [1][2][3] Group 1: Supercomputer and AI Factory - The supercomputer will serve as an "AI factory," managing the entire AI lifecycle from data ingestion to high-volume inference, utilizing over 1,000 B300 GPUs on a unified networking fabric [1][2] - This initiative is expected to enable rapid learning and iteration, allowing scientists to train AI models on millions of experiments, significantly expanding drug discovery capabilities [3][4] Group 2: Applications and Benefits - Beyond drug discovery, the supercomputer will help shorten development cycles, improve medical imaging, and enhance manufacturing processes through digital twins and robotic technologies [4][5] - The AI models developed will be accessible via Lilly TuneLab, a collaborative platform aimed at expanding access to advanced discovery tools across the biopharma ecosystem [3][4] Group 3: Strategic Vision - Lilly aims to shift from using AI as a tool to embracing it as a scientific collaborator, embedding intelligence into workflows to deepen understanding of diseases and improve patient outcomes [5] - The company is committed to sustainability, ensuring the supercomputer operates on 100% renewable electricity and utilizes existing infrastructure for cooling [5]

Core Insights - Recursion will host a public earnings call on November 5, 2025, at 8:00 am ET to provide business updates and report its Q3 2025 financial results [1][2] Company Overview - Recursion (NASDAQ: RXRX) is a clinical stage TechBio company focused on decoding biology to improve lives, utilizing its Recursion OS platform to generate extensive biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to analyze trillions of relationships in biology and chemistry, operating at a large experimental scale with millions of wet lab experiments weekly [3] - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, with additional offices in Montréal, New York, London, and the Oxford area [4]